PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Hemspan states that it designs bio-based building systems and products for construction by combining modern methods, technology and hemp to produce net-zero carbon solutions. The company argues that every time an average house is built, the CO2 emitted by the manufacture, transport and assembly of the materials used is around 50 to 60 tonnes. Hemspan says that one hectare of UK-grown industrial hemp can absorb 11 tonnes of CO2 each year with regeneratively farmed hemp capable of sequestering a further 6 tonnes per hectare of CO2 into the soil each year. Hemspan intends to activate significant demand for hemp farming in the UK and develop processing technologies to reduce reliance on imports and enable large scale manufacturing of bio-based cladding and insulation products that spin out of R&D programmes. It asserts that the global industrial hemp market is expected to grow at 25% CAGR reaching US$ 27 billion by 2028. It aims to be a contender in this segment.
days to go:
Expired
investment:
£200,000
Warwick Acoustics produces Electrostatic Audio Systems for the auto industry. The company is partnered with various car Original Equipment Manufacturers and Tier 1 suppliers to produce and distribute automotive solutions.
days to go:
Expired
investment:
Withheld
The world's first automated suturing tools for safe closure of standard and endoscopic wounds. Sutrue have already patented their devices and use industry-standard needles to offer clinical quality with improved speed and accuracy at the touch of a button. Needles are held in disposable cartridges as a safety feature to prevent injury when piercing skin with contaminated needles. This protects staff both during and after surgery for those working in medical and veterinary environments.
Sutrue is raising finance for the production process of their equipment, as well as applying for CE regulation via medical evaluations to receive approval to deploy their products in human and animal surgeries.
days to go:
Expired
investment:
Withheld
Oxford Nanoimaging (ONI) is an offshoot company, born from the biological physics lab at Oxford University, that specialises in super-resolution microscopy. Its innovation, Nanoimager, is a super-resolution fluorescence and portable microscope that is capable of real-time 3D localization analysis and rendering. It has multiple applications in a variety of fields such as viral particle imaging, quantitative cellular imaging, epigenetic mapping, and many more. ONI states that the Nanoimager can align and analyse samples, and then upload the results onto a computer for deeper graphical and data examination. ONI is also supporting the global effort into research and diagnostics to tackle the COVID-19 pandemic and finds the Nanoimager uniquely suited to this task. The company plans to use the investment to grow its business and ensure more institutions and researchers adopt its technology.
days to go:
Expired
investment:
Withheld
Lightpoint Medical is a technology company that is a pioneer in developing and marketing precision-guided cancer surgery. Surgeons aren't able to see if the cancerous tissue has been removed in its entirety or not during a surgery. To better this situation, the company has developed an imaging technology based on PET radiopharmaceuticals, more precisely, Cerenkov Luminescence Imaging (CLI), which helps surgeons to detect cancer in a real-time during surgery. The company's first product has received marketing authorisation, i.e., the CE (European Conformity) Mark. A second product, a laparoscopic device for prostate cancer is in development. A non-clinical device has also been released. For its efforts, Lightpoint Medical won the 'Best in Show' Award at the 2014 MedTech Investing Europe Conference. The company aims to utilise the investment to scale its business.
days to go:
Expired
investment:
Withheld
Metal matrix composite components and materials, primarily comprised of aluminium for use in the engineering and manufacturing industries. Alvant specialise in designing, developing and producing the composite for well-known clients such as Ford and Safran.
In the last financial year, Alvant achieved a turnover of almost £617k and has invested more than £10m towards manufacturing and testing their own product. Alvant is now raising funds to distribute their components to a wider market and expand the number of commercial applications that would benefit from their materials.
days to go:
Expired
investment:
£2,105,001
